FP-016

FP-016 is an early-stage sustained-release formulation being developed by Foresee Pharmaceuticals for the treatment of neurology and psychiatry disorders. The drug is built upon Foresee's proprietary Stabilized Injectable Formulation (SIF) technology, which is engineered to provide long-acting delivery of therapeutics to improve patient adherence and therapeutic outcomes. The SIF platform typically involves a polymer-based system that allows for a stable, ready-to-use injection with controlled release properties over extended periods. While the specific active ingredient and molecular target for FP-016 are currently undisclosed, the asset is positioned within the company's central nervous system (CNS) pipeline and is in the research or preclinical phase of development.